Background: Biofilm-associated Pseudomonas aeruginosa infections in cystic fibrosis have limited treatment options. Ceftolozane/tazobactam is a relatively recently available β-lactam/β-lactamase inhibitor combination that has been shown to have preserved activity against difficult-to-treat P. aeruginosa isolates. However, the effectiveness of ceftolozane/tazobactam (C/T), in monotherapy and combination with tobramycin (TOB), has not yet been characterised for the pharmacokinetics […]
Cornelia Landersdorfer
- PAGANZ Inc committee member
- PAGANZ Inc Society Member
- Monash University
Author Archive | Cornelia Landersdorfer
Population modelling of lithium in paediatric patients with bipolar disorder: implications for dosing
January 16, 2015
Authors Cornelia B Landersdorfer (1), Robert L Findling (2), Perdita Taylor-Zapata (3), Carl M J Kirkpatrick (1).
Affiliations 1. Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, VIC, AUS; 2. Child and Adolescent Psychiatry, Johns Hopkins University, Baltimore, MD, USA; 3. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), NIH, Bethesda, MD, USA;
Presentation type Oral
Presenters Cornelia B Landersdorfer
Introduction. Bipolar I disorder (BP-I) leads to substantive psychosocial dysfunction. Lithium is well-established for treating BP-I in adults, however there is a paucity of information in paediatrics. Aims. To characterise the pharmacokinetics/pharmacodynamics (PK/PD) of lithium in paediatrics and to predict lithium concentrations and clinical effects for novel dosage regimens. Methods. Observed lithium concentrations and Young […]
Population pharmacokinetics of colistin and its prodrug colistin methanesulfonate following intravenous and pulmonary dosing in sheep
January 24, 2014
Authors Cornelia B Landersdorfer (1), Tri-Hung Nguyen (2), LT Lieu (2), RJ Bischof (3), Michelle P McIntosh (2).
Affiliations 1. Centre for Medicine Use and Safety, Monash University, Parkville, VIC, Australia; 2. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia; 3. Biotechnology Research Laboratories, School of Biomedical Sciences, Monash University, Clayton, VIC, Australia;
Presentation type Oral
Presenters Cornelia Landersdorfer
Background. Colistin is administered as its inactive prodrug colistin methanesulfonate (CMS) and is increasingly used as last-line therapy against multidrug-resistant Gram-negative bacteria. While pulmonary dosing of CMS is utilised in lung infections to reduce the risk of nephrotoxicity and neurotoxicity, there is a dearth of pharmacokinetic (PK) information on colistin and CMS. Quantitatively characterising the […]
Mechanism-based modelling and sequential dosing to elucidate subpopulation synergy for antibiotic combinations
February 4, 2013
Authors Cornelia B Landersdorfer (1,2), Neang S Ly (2), Hongmei Xu (2), Brian T Tsuji (2), Jurgen B Bulitta (1,2).
Affiliations 1. Centre for Medicine Use and Safety, Monash University, Parkville, VIC, Australia; 2. School of Pharmacy and Pharmaceutical Sciences, SUNY Buffalo, NY, USA;
Presentation type Oral
Presenters Cornelia Landersdorfer
Background: Rational and prospective approaches to optimize antibiotic combination therapy are scarce. Due to the emerging global healthcare crisis caused by multidrug-resistant bacteria, more efficient and quantitative approaches to optimize combination therapy are urgently required. Nisin, a peptide antibiotic affecting pore formation in bacterial membranes and preventing peptidoglycan synthesis, is rapidly bactericidal against multiple-resistant Staphylococcus […]
Population Modelling of Vildagliptin as an Inhibitor and Substrate of Dipeptidylpeptidase IV and its Effects on Glucagon-Like Peptide 1, Glucose, and Insulin
January 31, 2012
Authors Cornelia B Landersdorfer (1,2), Yan-Ling He (3), William J Jusko (2)
Affiliations (1) Centre for Medicine Use and Safety, Monash University, Parkville, VIC, (2) School of Pharmacy and Pharmaceutical Sciences, SUNY Buffalo, NY, USA;, (3) Translational Science-Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Presentation type Oral
Presenters Cornelia Landersdorfer
Background. Vildagliptin acts by inhibiting dipeptidyl peptidase IV (DPP-4), thereby increases active GLP-1 (glucagon-like peptide 1) concentrations and decreases plasma glucose in diabetic patients. Objectives. To develop a mechanism-based population PK/PD model that simultaneously describes and predicts vildagliptin pharmacokinetics and its effects on DPP-4 activity and the underlying glucose-insulin-GLP-1 system. Methods. Data used for model […]